Payment overview · 2025
General Payments
$1,796.61
28 reported records · 12 companies
Healthcare provider profile · identity verified
Michael J Gurevitch, M.D
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · PASADENA, CA · NPI 1629016894
Verified facts
What the public records show
CMS Open Payments records show Michael J Gurevitch, M.D received $1,796.61 in general payments during 2025 across 28 reported records.
Fisher & Paykel Healthcare Limited accounted for 48.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Fisher & Paykel Healthcare Limited | Unresolved — no canonical attribution shown | $875.00 | 48.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $176.38 | 9.8% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $157.43 | 8.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $150.00 | 8.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $127.40 | 7.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $121.81 | 6.8% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $43.58 | 2.4% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $36.07 | 2.0% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $30.21 | 1.7% | 1 | 2025 |
| Liquidia Technologies, Inc. | Unresolved — no canonical attribution shown | $29.84 | 1.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.55 | 1.4% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $24.34 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $921.61 | 26 |
| Consulting Fee | $875.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FISHER & PAYKEL HEALTHCARE Normalized: fisher paykel healthcare |
Device | Fisher & Paykel Healthcare Limited | $875.00 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $155.37 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $127.40 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $121.81 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $43.58 | 2 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $43.58 | 2 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $43.58 | 2 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $43.58 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $36.07 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $30.21 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $30.21 | 1 | 2025 |
Source payment records
|
|||||
| YUTREPIA Normalized: yutrepia |
Drug | Liquidia Technologies, Inc. | $29.84 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $3.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 252 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
252 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 322 | 128 |
| Breo Ellipta | Fluticasone/Vilanterol | 257 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 252 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 45 |
| Azithromycin | Azithromycin | 129 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 95 | 14 |
| Famotidine | Famotidine | 72 | 13 |
| Furosemide | Furosemide | 72 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 72 | 11 |
| Losartan Potassium | Losartan Potassium | 63 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 62 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 51 | 16 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 51 | 16 |
| Metformin Hcl | Metformin Hcl | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Omeprazole | Omeprazole | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Alprazolam | Alprazolam | 36 | 11 |
| Carvedilol | Carvedilol | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Simvastatin | Simvastatin | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 12 |
| Allopurinol | Allopurinol | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 11 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Gabapentin | Gabapentin | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,796.61 · 28 records | Fisher & Paykel Healthcare Limited | AIRSUPRA, Arikayce, BREZTRI, Brinsupri, CHARTIS CATHETER, FISHER & PAYKEL HEALTHCARE, FREESTYLE LIBRE 3, MOUNJARO, NUCALA, NUZYRA, Ohtuvayre, PEMGARDA, PULMONX CHARTIS TABLET CONSOLE, TRELEGY ELLIPTA, YUPELRI, YUTREPIA, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error